PT  - JOURNAL ARTICLE
AU  - Schöley, Jonas
TI  - Robustness and bias of European excess death estimates in 2020 under varying model specifications
AID  - 10.1101/2021.06.04.21258353
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.04.21258353
4099  - http://medrxiv.org/content/early/2021/06/09/2021.06.04.21258353.short
4100  - http://medrxiv.org/content/early/2021/06/09/2021.06.04.21258353.full
AB  - Various procedures are in use to calculate excess deaths during the ongoing COVID-19 pandemic. Using weekly death counts from 20 European countries, we evaluate the robustness of excess death estimates to the choice of model for expected deaths and perform a cross-validation analysis to assess the error and bias in each model’s predicted death counts. We find that the different models produce very similar patterns of weekly excess deaths but disagree substantially on the level of excess. While the exact country ranking along percent excess death in 2020 is sensitive to the choice of model the top and bottom ranks are robustly identified. On the country level, the 5-year average death rate model tends to produce the lowest excess death estimates, whereas high excess deaths are produced by the popular 5-year average death count and Euromomo-style Serfling models. Cross-validation revealed these estimates to be biased under a causal interpretation of “expected deaths had COVID-19 not happened.”Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study only uses publicly available population dataFunding StatementROCKWOOL Foundation's Excess Deaths grantAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code to replicate the results in this paper are available at https://github.com/jschoeley/rbx2020. https://github.com/jschoeley/rbx2020